GRI Bio Schedules Virtual 2025 Annual Meeting, Board Backs All Proposals
Ticker: GRI · Form: DEF 14A · Filed: Jul 11, 2025 · CIK: 1824293
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Shareholder Vote, Corporate Governance, Virtual Meeting, Biotechnology, Pharmaceuticals
Related Tickers: GRI
TL;DR
**GRI Bio's virtual annual meeting is a procedural formality, but shareholders better vote on those board-backed proposals or risk missing out on shaping the company's future!**
AI Summary
GRI Bio, Inc. has filed a Definitive Proxy Statement (DEF 14A) on July 11, 2025, for its 2025 Annual Meeting of Stockholders, scheduled for August 13, 2025, at 11:00 a.m. Eastern Time. The company, a pharmaceutical preparations firm (SIC 2834), will conduct the meeting virtually via live audio webcast at www.virtualshareholdermeeting.com/GRI2025, citing increased stockholder attendance, improved efficiency, and reduced costs and environmental impact as reasons. The board of directors recommends approval of all proposals presented at the Annual Meeting. Stockholders are encouraged to vote by proxy via internet, telephone, or mail, even if they plan to attend the virtual meeting. The filing does not disclose specific revenue or net income figures, nor does it detail key business changes or strategic outlook beyond the procedural aspects of the annual meeting. Risks are implicitly related to shareholder governance and voting on board-recommended proposals.
Why It Matters
This DEF 14A filing signals GRI Bio's commitment to shareholder engagement through a virtual annual meeting, a trend gaining traction across the pharmaceutical industry for its efficiency and accessibility. For investors, it's a critical opportunity to vote on board-recommended proposals, which could influence the company's future governance and strategic direction. Employees and customers might see this as a sign of operational modernization, while the broader market observes how biotech firms like GRI Bio adapt to digital-first shareholder interactions, potentially setting new competitive standards for transparency and participation.
Risk Assessment
Risk Level: low — The risk level is low as this is a routine Definitive Proxy Statement (DEF 14A) primarily announcing the 2025 Annual Meeting of Stockholders on August 13, 2025. It does not contain information about significant financial distress, major litigation, or adverse operational changes. The primary 'risk' is the potential for shareholders to not engage with the voting process.
Analyst Insight
Investors should review the full proxy statement for specific proposals and vote their shares by proxy before the August 13, 2025 meeting. Active participation in governance is crucial, even for routine meetings, to ensure alignment with company strategy.
Key Numbers
- 2025-07-11 — Filing Date (Date the DEF 14A was filed with the SEC)
- 2025-08-13 — Annual Meeting Date (Date of GRI Bio, Inc.'s 2025 Annual Meeting of Stockholders)
- 11:00 a.m. ET — Annual Meeting Time (Scheduled start time for the virtual meeting)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 001-40034 — SEC File Number (Unique identifier for GRI Bio, Inc.'s SEC filings)
Key Players & Entities
- GRI Bio, Inc. (company) — Registrant filing the DEF 14A
- United States Securities and Exchange Commission (regulator) — Governing body for SEC filings
- August 13, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
- 11:00 a.m. Eastern Time (time) — Scheduled start time of the Annual Meeting
- July 11, 2025 (date) — Filing date of the DEF 14A
- 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037 (address) — Business address of GRI Bio, Inc.
- 001-40034 (number) — SEC File Number for GRI Bio, Inc.
- 0001824293 (number) — Central Index Key (CIK) for GRI Bio, Inc.
- www.virtualshareholdermeeting.com/GRI2025 (website) — Virtual meeting platform for GRI Bio's 2025 Annual Meeting
- Board of Directors (person) — Recommends approval of all proposals
FAQ
When is GRI Bio, Inc.'s 2025 Annual Meeting of Stockholders?
GRI Bio, Inc.'s 2025 Annual Meeting of Stockholders is scheduled for Wednesday, August 13, 2025, at 11:00 a.m. Eastern Time. This information is detailed in the Definitive Proxy Statement (DEF 14A) filed on July 11, 2025.
How can stockholders attend GRI Bio's 2025 Annual Meeting?
Stockholders can attend GRI Bio's 2025 Annual Meeting virtually via a live audio webcast on the internet by visiting www.virtualshareholdermeeting.com/GRI2025. The company has opted for a virtual format to enhance attendance and efficiency, as stated in the July 11, 2025 filing.
What is the purpose of GRI Bio's DEF 14A filing?
The DEF 14A filing by GRI Bio, Inc. serves as a Definitive Proxy Statement, providing stockholders with information about the upcoming 2025 Annual Meeting, the business to be conducted, and details necessary for voting their shares. It was filed on July 11, 2025, in accordance with SEC regulations.
What does GRI Bio's board of directors recommend regarding the proposals?
The board of directors of GRI Bio, Inc. recommends the approval of each of the proposals presented at the 2025 Annual Meeting. This recommendation is explicitly stated in the DEF 14A filed on July 11, 2025, encouraging stockholders to vote in favor.
What are the benefits of GRI Bio holding a virtual annual meeting?
GRI Bio, Inc. believes hosting a virtual annual meeting enables greater stockholder attendance and participation from any location, improves meeting efficiency, enhances communication with stockholders, and reduces the cost and environmental impact. These benefits were cited in the July 11, 2025 DEF 14A filing.
How can GRI Bio stockholders vote their shares for the Annual Meeting?
GRI Bio stockholders can cast their vote either at the virtual Annual Meeting or by proxy. Voting options include over the internet, by telephone, or by mail, as outlined in the accompanying Proxy Statement filed on July 11, 2025.
What is GRI Bio, Inc.'s business address?
GRI Bio, Inc.'s business address is 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037. This address is consistently listed across the company's SEC filings, including the DEF 14A from July 11, 2025.
What is the Central Index Key (CIK) for GRI Bio, Inc.?
The Central Index Key (CIK) for GRI Bio, Inc. is 0001824293. This unique identifier is used by the SEC to identify the company in its electronic filing system, as shown in the DEF 14A filed on July 11, 2025.
What industry is GRI Bio, Inc. classified under?
GRI Bio, Inc. is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. This classification indicates its primary business operations within the pharmaceutical sector, as detailed in the July 11, 2025 filing.
Are there any specific financial figures or risks mentioned in this GRI Bio DEF 14A?
This specific DEF 14A filing from GRI Bio, Inc. on July 11, 2025, is primarily procedural, focusing on the upcoming 2025 Annual Meeting. It does not contain specific revenue, net income figures, or detailed discussions of financial risks beyond the general context of shareholder governance. The main 'risk' is the potential for shareholders to not participate in voting on board-recommended proposals.
Industry Context
GRI Bio, Inc. operates within the Pharmaceutical Preparations industry (SIC 2834). This sector is characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection.
Regulatory Implications
As a pharmaceutical preparations company, GRI Bio, Inc. is subject to extensive regulatory scrutiny regarding drug development, manufacturing, and marketing. The DEF 14A filing itself is a regulatory requirement under the Securities Exchange Act of 1934, ensuring transparency for investors.
What Investors Should Do
- Review the Proxy Statement thoroughly.
- Vote by proxy.
- Attend the virtual Annual Meeting.
Key Dates
- 2025-07-11: Filing of Definitive Proxy Statement (DEF 14A) — Provides shareholders with information regarding the upcoming annual meeting and proposals for voting.
- 2025-08-13: 2025 Annual Meeting of Stockholders — Key date for shareholder voting on corporate matters, including board recommendations.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC by a company soliciting shareholder votes for its annual meeting. (This document outlines the agenda, proposals, and information necessary for shareholders to make informed voting decisions at GRI Bio, Inc.'s annual meeting.)
- SIC Code
- Standard Industrial Classification code used to categorize businesses by industry. (GRI Bio, Inc. is classified under SIC code 2834, indicating its primary business is in Pharmaceutical Preparations.)
- Virtual Annual Meeting
- A shareholder meeting conducted online via live audio webcast, rather than in person. (GRI Bio, Inc. is holding its 2025 Annual Meeting virtually to increase attendance, efficiency, and reduce costs and environmental impact.)
Year-Over-Year Comparison
This filing is a routine DEF 14A for the 2025 Annual Meeting. As it focuses on procedural aspects of the meeting and does not disclose detailed financial performance or strategic shifts, a direct comparison of key metrics like revenue growth or margin changes to a previous filing is not possible from this document alone. The primary change noted is the shift to a virtual meeting format for increased accessibility and efficiency.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 11, 2025 by Board of Directors regarding GRI Bio, Inc. (GRI).